Search

Displaying results 1551 - 1560 of 2413 in total
  1. Drug

    PSI-697

    go.drugbank.com/drugs/DB12211
    Investigational

    PSI-697 has been used in trials studying the treatment of Scleritis.

    Categories: P-Selectin
  2. Drug

    Bergapten

    go.drugbank.com/drugs/DB12216
    Investigational

    Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  3. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  4. Drug

    Seviteronel

    go.drugbank.com/drugs/DB12275
    Investigational

    Seviteronel has been used in trials studying the treatment of CRPC, Prostate Cancer, and Castration-resistant Prostate Cancer.

    Categories: Cytochrome P-450 Enzyme Inhibitors
  5. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  6. Drug

    Doravirine

    go.drugbank.com/drugs/DB12301
    ApprovedInvestigational

    Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (10...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  8. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment o...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Sagopilone

    go.drugbank.com/drugs/DB12391
    Investigational

    Sagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others. It is a so-called fully synthetic epothilone and is the first such compound to be in clinic...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Sulforaphane

    go.drugbank.com/drugs/DB12422
    Investigational

    Sulforaphane is under investigation for the treatment of Autism Spectrum Disorder. It is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli.

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors